The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50 ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virusvaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...